Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Hj Mathijssen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|January 17, 2012
Danusertib, an aurora kinase inhibitorHielke J Meulenbeld, Ron Hj Mathijssen, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2022
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?Emma C Hulshof, Mirjam de With, Geert-Jan Creemers, et al.
Pharmacogenomics|July 20, 2023
<i>UGT1A1</i> genotype-guided dosing of irinotecan: time to prioritize patient safetySofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, et al.
Pharmacogenomics|August 18, 2016
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicitySander Bins, Anne Lenting, Samira El Bouazzaoui, et al.
The Cochrane Database of Systematic Reviews|November 29, 2017
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancerVincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, et al.
Pharmacogenomics|April 1, 2015
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicityClaudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, et al.
Pharmacogenomics|December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanomaAndrew Kl Goey, Mirjam de With, Bram C Agema, et al.
British Journal of Cancer|August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancerEllen S de Morrée, René Böttcher, Robert J van Soest, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|January 17, 2012
Danusertib, an aurora kinase inhibitorHielke J Meulenbeld, Ron Hj Mathijssen, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2022
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?Emma C Hulshof, Mirjam de With, Geert-Jan Creemers, et al.
Pharmacogenomics|July 20, 2023
<i>UGT1A1</i> genotype-guided dosing of irinotecan: time to prioritize patient safetySofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, et al.
Pharmacogenomics|August 18, 2016
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicitySander Bins, Anne Lenting, Samira El Bouazzaoui, et al.
The Cochrane Database of Systematic Reviews|November 29, 2017
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancerVincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, et al.
Pharmacogenomics|April 1, 2015
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicityClaudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, et al.
Pharmacogenomics|December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanomaAndrew Kl Goey, Mirjam de With, Bram C Agema, et al.
British Journal of Cancer|August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancerEllen S de Morrée, René Böttcher, Robert J van Soest, et al.
Pageof 1